|Systematic (IUPAC) name|
|Mol. mass||354.9 g/mol|
Zicronapine (zye-KRON-a-peen, previously known as Lu 31-130) is an atypical antipsychotic medication currently under development by H. Lundbeck A/S. In phase II studies zicronapine did show statistical significant separation from placebo and very convincing efficacy and safety data when compared to olanzapine.
- "The clinical phase III programme commenced on zicronapine". January 20, 2011. Retrieved 6 February 2014.
- "Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia - planning for continued clinical work". December 18, 2009. Retrieved 6 February 2014.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|
|This mental health-related article is a stub. You can help Wikipedia by expanding it.|